# Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial

> **NCT06957093** · NA · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 400 (estimated)

## Conditions studied

- Diabetes Mellitus Type 2 (T2DM)
- Artificial Intelligence (AI)

## Interventions

- **OTHER:** artificial intelligence
- **OTHER:** Routine diagnosis and treatment group for diabetes

## Key facts

- **NCT ID:** NCT06957093
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06957093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06957093, "Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06957093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*